The global cell and gene therapy manufacturing quality control (QC) market is projected to grow from USD 2.71 billion in 2024 to USD 16.32 billion by 2034, at a compound annual growth rate (CAGR) of 19.8% from 2025 to 2034. This growth is driven by rising demand for personalized medicine, advancements in therapy technologies, increased R&D investment, and expanding regulatory approvals. Key players include bioMérieux SA, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, QIAGEN, Charles River Laboratories International, Inc., Lonza Group AG, Merck KGaA, Intertek Group plc, Thermo Fisher Scientific, Inc., Eurofins Scientific S.E., F. Hoffmann-La Roche Ltd., Catalent, Wuxi AppTec, Takara Bio Inc, Oxford Biomedica plc, FUJIFILM Holdings Corporation, Danaher (Cytiva), Sartorius AG, AGC Biologics, and others. North America is expected to dominate the market due to strong healthcare infrastructure and R&D investment, while Europe holds a significant share through favorable policies and industry collaboration. Challenges include complex manufacturing processes, high costs, and difficulties in scaling production. Recent developments include Thermo Fisher Scientific establishing a sterile drug facility in Singapore in February 2024 and Merck creating a second facility in Carlsbad, California, in April 2020 for its BioReliance® viral and gene therapy services.

The U.S. pharmaceutical CDMO market is projected to grow from USD 39.14 billion in 2025 to USD 68.57 billion by 2034, at a CAGR of 6.43%. The market is driven by rising demand for biologics, biosimilars, and advanced therapies such as oncology treatments, cell and gene therapies, and mRNA vaccines. Key growth factors include scalability, cost-effectiveness, regulatory expertise, and adoption of digital technologies and continuous manufacturing. The API segment dominates by product, the commercial segment by workflow, and oncology by application. The large pharmaceutical companies segment is the leading end-user and is expected to grow rapidly. Recent developments include ESTEVE acquiring Regis Technologies, Purdue University launching an AI-driven national initiative with industry leaders, and Benuvia Operations signing a multi-year supply agreement with a major U.S. pharmaceutical company. Major players include Adare Pharma Solutions, AGC Biologics, Agilent Technologies, Catalent Pharma Solutions, Exela Pharma Sciences, PCI Pharma Services, Pfizer CentreOne, Scorpius BioManufacturing, Sharp Services, Thermo Fisher Scientific, and UPM Pharmaceuticals, Inc.

The U.S. pharmaceutical CDMO market is projected to grow from USD 39.14 billion in 2025 to USD 68.57 billion by 2034, at a CAGR of 6.43%. This growth is driven by rising demand in therapeutic areas like oncology and chronic conditions, increased adoption of digital technologies and advanced manufacturing, and the outsourcing of production by pharmaceutical companies to leverage scalability, cost-effectiveness, and regulatory expertise. Key trends include expansion in biologics, gene and cell therapies, and the growing role of AI in manufacturing. Major developments include Agenus Inc.'s $141M partnership with Zydus, ESTEVE's acquisition of Regis Technologies, and Purdue University's collaboration on AI-driven manufacturing. The market is also seeing strong growth in specialized segments such as mRNA therapeutics, advanced therapies, and active pharmaceutical ingredients (APIs), with several sub-markets growing at higher CAGRs. Key players include Adare Pharma Solutions, AGC Biologics, Catalent Pharma Solutions, Exela Pharma Sciences, PCI Pharma Services, Pfizer CentreOne, Scorpius BioManufacturing, Sharp Services, Thermo Fisher Scientific, and UPM Pharmaceuticals, Inc.

The global contract manufacturing market is projected to grow from $686.4 billion in 2025 to $968.7 billion by 2030, at a compound annual growth rate (CAGR) of 7.1%. This growth is driven by rising demand for outsourcing, expansion in consumer electronics, technological advances such as automation and AI, increased healthcare infrastructure investment, and stronger collaborations between pharmaceutical companies and contract manufacturers. The Asia-Pacific region led the market in 2024 with a 38.4% share and is expected to reach $354.4 billion by 2030. The report analyzes market segments by contract type, distribution channel, and end-use industry, with consumer electronics expected to dominate through 2030. It also highlights emerging startups like Mefron, IndyGeneUS Bio, and AtomVie, and profiles major industry players including Flex Ltd., Jabil Inc., and HON HAI Precision Industry Co. Ltd.

A global market analysis report by Worldwide Market Reports examines the transformation of the viral vector and plasmid DNA manufacturing market, driven by technological innovation, regulatory alignment, and sustainability efforts. The report provides insights into market growth, competitive dynamics, and regional trends across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with forecasts through 2032. It highlights key drivers such as technology adoption and supply chain resilience, while addressing challenges like geopolitical shifts and cost optimization. The analysis includes segmentation by product type and application, and offers strategic tools for investors, executives, and policymakers to guide international expansion and risk mitigation.